A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
S
Samir Gupta, MD
Primary Investigator
Overview
The purpose of this study is to provide remdesivir (RDV) to participants with moderate COVID-19.
Description
Participants will be randomly assigned to receive either continued SOC therapy together with intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2-5, or continued SOC therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2-10.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
COVID-19
-
Age: Between 12 Years - 100 Years
-
Gender: All
Individuals at least 12 years of age currently hospitalized with COVID-19.
Individuals requiring mechanical ventilation will not be eligible.
Women who are pregnant or breastfeeding will not be eligible.
Updated on
20 Nov 2022.
Study ID: 2003894138
